Krystal Biotech Reports 80% Lesion Regression in KB113 Gorlin Syndrome Pilot Study

Key highlights

• Over 80% of assessed basal cell carcinoma lesions regressed across three pilot study patients
• Evidence of a systemic abscopal effect was observed in lesions not directly injected with KB113
• Histological analysis confirmed the complete clearance of an injected lesion in every participant
• KB113 was well-tolerated with only mild-to-moderate and transient adverse events reported
• The therapy utilizes an HSV-1 vector to express therapeutic cytokines IL-2 and IL-12 directly in tumors

Clinical Trial Outcomes

Krystal Biotech (KRYS) announced positive results from its Gorlin Syndrome Pilot Study evaluating KB113, an intratumoral immunotherapy. The trial involved three adult patients who received six doses of the therapy over a 14-week treatment window. Investigators observed that more than 80% of the assessed basal cell carcinoma lesions reduced in size. Significantly, regression occurred in both injected tumors and non-injected landmark lesions, a phenomenon termed the abscopal effect. This suggests the treatment induces a localized immune response that extends systemically to combat distant disease. Histological confirmation of complete clearance was achieved for at least one injected lesion in each patient, and no severe adverse events were identified during the study period.

Therapeutic Significance

For patients with Gorlin syndrome, the lifelong emergence of multiple basal cell carcinomas creates an immense treatment burden, often requiring repetitive and potentially disfiguring surgeries. The observed antitumor responses across both injected and non-injected lesions represent a potential paradigm shift in management. By leveraging the STAR-D platform to deliver interleukin-2 (IL-2) and interleukin-12 (IL-12) directly into the tumor microenvironment, KB113 aims to promote sustained, localized immune activation. This approach could offer a non-surgical alternative for patients who might otherwise face hundreds of procedures over their lifetime to manage recurrent skin cancers, significantly improving long-term quality of life and physical outcomes.

Business and Pipeline Strategy

Krystal Biotech is leveraging its success with VYJUVEK, the first FDA-approved redosable gene therapy, to expand its footprint in dermatology and oncology. The company's proprietary Skin TARgeted Delivery platform (STAR-D) uses a modified HSV-1 vector to deliver genetic material to skin cells. While VYJUVEK focuses on rare skin diseases like dystrophic epidermolysis bullosa, the KB113 program represents a strategic expansion into the oncology sector. The company is currently executing on multiple milestones, including the anticipated top-line registrational trial readout for KB803 in late 2026 and the ongoing commercial launch of VYJUVEK in European markets such as Spain and Italy, supported by a robust balance sheet and growing revenue streams.

Financial and Market Context

Financially, Krystal continues to scale its commercial operations, reporting Q2 2026 VYJUVEK net revenue of $119.2 million. The company carries a market capitalization of approximately $9.79 billion and has seen stable price performance despite broader sector volatility. Management has reaffirmed its 2026 guidance for non-GAAP operating expenses between $175 million and $195 million, reflecting a disciplined approach to research and development. With a P/E ratio of 40.23x, the market appears to be pricing in continued growth from both the core dermatology franchise and the expanding oncology pipeline. The successful proof-of-concept for KB113 provides further validation for the company's modular viral vector platform across diverse therapeutic indications.

Management commentary

“The observed antitumor responses with KB113 across both injected and non-injected lesions represent encouraging preliminary findings that strongly support its continued clinical development.”

Krystal Biotech, Inc. · financial snapshot

Share price	$330.69
Market cap	$9.8B
Revenue (annual)	$389M
P/E (TTM)	40.2×
1-month price change	-2.75%
Sector	HealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.